Exact Sciences Shares Rise after Analyst Upgrade | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Shares of Exact Sciences climbed almost 16 percent today after investment firm Rodman & Renshaw upgraded its stock to Market Outperform from Perform.

Rodman & Renshaw also increased the 18-month price target on Exact Sciences' shares to $12 from $7. Shares of the company on Nasdaq closed at $7.46.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.